Chargement de l’entreprise
Just reported
Q3 2026 results
From Generate Biomedicines's results release of 12 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
4,2M $US
-56 % y/y
-33 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,68 $US
Guided
—
No guide given
Operating income, GAAP
Actual
-91,5M $US
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $USA+
EXELExelixis, Inc.16,8B $USA+
JAZZJazz Pharmaceuticals plc15,5B $USA
TECHBIO-Techne Corp11,4B $USA+
HALOHalozyme Therapeutics, Inc.11,4B $USA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Research collaboration payments100 %
Les parts du chiffre d'affaires sont des estimations pour six months ended June 30, 2026, pas des chiffres tirés d'un document officiel.
Ce qu'elle vend3
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
Qui l'achète2
- Amgen, which pays for research under a collaboration agreement.
- Novartis, which pays for research under a collaboration agreement.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Current revenue depends on research work under agreements with Amgen and Novartis; the company says the work under both agreements is nearing completion.
- 2Clinical research and manufacturing rely in part on outside providers, including contract research organizations and contract development and manufacturing organizations.
- 3Developing and selling medicines depends on clinical trials and regulatory approval.
Ce qui pourrait mal tourner
- 1GB-0895 and the other experimental medicines may not prove safe and effective in clinical trials or receive regulatory approval.
- 2The company has no medicine sales, and its current collaboration revenue depends on research agreements whose work is nearing completion.
- 3The company has ongoing operating losses and expects to need additional funding to continue research and clinical development; it may not obtain that funding on acceptable terms or at all.
À propos de Generate Biomedicines, Inc.
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
- Siège
- Cambridge, Massachusetts
- Fondée en
- 2018
- Cotée sur
- NASDAQ
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Generate Biomedicines, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
